NASDAQ:RDUSRadius Health Stock Price, Forecast & News

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS stock has decreased by 25.2% and is now trading at $12.01.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Radius Health.

Radius Health is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Radius Health.

Radius Health will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Radius Health Inc (NASDAQ:RDUS) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.09. The biopharmaceutical company had revenue of $47.92 million for the quarter, compared to analyst estimates of $46.77 million.
View Radius Health's earnings history.

8 Wall Street analysts have issued 1 year target prices for Radius Health's stock. Their forecasts range from $18.00 to $40.00. On average, they anticipate Radius Health's stock price to reach $25.71 in the next year. This suggests a possible upside of 114.1% from the stock's current price.
View analysts' price targets for Radius Health.

Headlines about RDUS stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Radius Health.

Some companies that are related to Radius Health include Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), Prestige Consumer Healthcare (PBH), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), I-Mab (IMAB), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), INDIVIOR PLC/S (INVVY), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS) and Y-mAbs Therapeutics (YMAB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), EXACT Sciences (EXAS), Cara Therapeutics (CARA), Amarin (AMRN), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Netflix (NFLX), ACADIA Pharmaceuticals (ACAD) and Micron Technology (MU).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (1.93%), Rhenman & Partners Asset Management AB (0.72%), Russell Investments Group Ltd. (0.30%), MERIAN GLOBAL INVESTORS UK Ltd (0.28%), Swiss National Bank (0.22%) and Mackay Shields LLC (0.16%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere.
View institutional ownership trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC.
View insider buying and selling activity for Radius Health.

RDUS stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Rhenman & Partners Asset Management AB, Rafferty Asset Management LLC, Swiss National Bank, Russell Investments Group Ltd., Virtus ETF Advisers LLC, Mackay Shields LLC, and ProShare Advisors LLC. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech.
View insider buying and selling activity for Radius Health.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RDUS stock can currently be purchased for approximately $12.01.

Radius Health has a market capitalization of $557.14 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

The official website for Radius Health is www.radiuspharm.com.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]